{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:06:16Z","timestamp":1759032376745},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,5,17]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> In schizophrenia, pathway-genotypes may be constructed by combining interrelated\nimmune biomarkers with changes in specific neurocognitive functions that represent aberrations\nin brain neuronal circuits. These constructs provide an insight on the phenome of schizophrenia and\nshow how pathway-phenotypes mediate the effects of genome X environmentome interactions on the\nsymptomatology\/phenomenology of schizophrenia. Nevertheless, there is a lack of knowledge how to\nconstruct pathway-phenotypes using Partial Least Squares (PLS) path modeling and Soft Independent\nModeling of Class Analogy (SIMCA).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>This paper aims to provide a step-by-step utilization guide for the construction of pathwayphenotypes\nthat reflect aberrations in the neuroimmune - brain circuit axis (NIBCA) in deficit schizophrenia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and Results:<\/jats:title>\n<jats:p>This NIBCA index is constructed using immune biomarkers (CCL-2, CCL-11,\nIL-1\u03b2, sIL-1RA, TNF-\u03b1, sTNFR1, sTNFR2) and neurocognitive tests (Brief Assessment of Cognition in\nSchizophrenia) predicting overall severity of schizophrenia (OSOS) in 120 deficit SCZ and 54 healthy\nparticipants. Using SmartPLS path analysis, a latent vector is extracted from those biomarkers and cognitive\ntests, which shows good construct reliability (Cronbach alpha and composite reliability) and replicability\nand which is reflectively measured through its NIBCA manifestations. This NIBCA pathwayphenotype\nexplains 75.0% of the variance in PHEMN (psychotic, hostility, excitation, mannerism and\nnegative) symptoms. Using SIMCA, we constructed a NIBCA pathway-class that defines deficit schizophrenia\nas a qualitatively distinct nosological entity, which allows patients with deficit schizophrenia to\nbe authenticated as belonging to the deficit schizophrenia class.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In conclusion, our nomothetic approach to develop a nomological network combining\nneuro-immune and neurocognitive phenome markers to predict OSOS and cross-validate a diagnostic\nclass generated replicable models reflecting the key phenome of the illness, which may mediate the effects\nof genome X environmentome interactions on the final outcome phenome features, namely symptomatology\nand phenomenology.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200128143948","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T13:34:57Z","timestamp":1580218497000},"page":"747-758","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia"],"prefix":"10.2174","volume":"20","author":[{"given":"Hussein K.","family":"Al-Hakeim","sequence":"first","affiliation":[{"name":"Department of Chemistry, College of Science, University of Kufa, Kufa, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas F.","family":"Almulla","sequence":"additional","affiliation":[{"name":"Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arafat H.","family":"Al-Dujaili","sequence":"additional","affiliation":[{"name":"Senior Clinical Psychiatrist, Faculty of Medicine, Kufa University, Kufa, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1871527317666181119115532","volume":"18","author":"Sirivichayakul S.","year":"2019","unstructured":"Sirivichayakul S.; Kanchanatawan B.; Thika S.; Carvalho A.F.; Maes M.; A new schizophrenia model: immune activation is associated with induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions. CNS Neurol Disord Drug Targets 2019,18(2),124-140","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12640-018-9937-8","volume":"35","author":"Sirivichayakul S.","year":"2019","unstructured":"Sirivichayakul S.; Kanchanatawan B.; Thika S.; Carvalho A.F.; Maes M.; Eotaxin, an endogenous cognitive deteriorating chemokine (ecdc), is a major contributor to cognitive decline in normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in schizophrenia patients. Neurotox Res 2019,35(1),122-138","journal-title":"Neurotox Res"},{"key":"ref=3","doi-asserted-by":"publisher","author":"Al-Hakeim H.K.","unstructured":"Al-Hakeim H.K.; Al-Mulla A.F.; Maes M.;  The neuro-immune\n\tfingerprint of major neuro-cognitive psychosis or deficit\n\tschizophrenia: a supervised machine learning study. Preprint ,\n\t2019, 2019050285.","DOI":"10.20944\/preprints201905.0285.v1"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1007\/s12035-018-1437-6","volume":"56","author":"Maes M.","year":"2019","unstructured":"Maes M.; Kanchanatawan B.; Sirivichayakul S.; Carvalho A.F.; In schizophrenia, deficits in natural igm isotype antibodies including those directed to malondialdehyde and azelaic acid strongly predict negative symptoms, neurocognitive impairments, and the deficit syndrome. Mol Neurobiol 2019,56(7),5122-5135","journal-title":"Mol Neurobiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s12640-018-9987-y","volume":"35","author":"Maes M.","year":"2019","unstructured":"Maes M.; Kanchanatawan B.; Sirivichayakul S.; Carvalho A.F.; In schizophrenia, increased plasma igm\/iga responses to gut commensal bacteria are associated with negative symptoms, neurocognitive impairments, and the deficit phenotype. Neurotox Res 2019,35(3),684-698","journal-title":"Neurotox Res"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.20944\/preprints201901.0108.v1","volume":"2019010108","author":"Maes M.","year":"2019","unstructured":"Maes M.; Sirivichayakul S.; Kanchanatawan B.; Carvalho A.F.; In schizophrenia, psychomotor retardation is associated with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde. Preprints 2019,2019010108","journal-title":"Preprints"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12640-019-00054-6","volume":"36","author":"Maes M.","year":"2019","unstructured":"Maes M.; Sirivichayakul S.; Kanchanatawan B.; Vodjani A.; Breakdown of the paracellular tight and adherens junctions in the gut and blood brain barrier and damage to the vascular barrier in patients with deficit schizophrenia. Neurotox Res 2019,36(2),306-322","journal-title":"Neurotox Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s12035-019-01737-z","volume":"57","author":"Roomruangwong C.","year":"2020","unstructured":"Roomruangwong C.; Noto C.; Kanchanatawan B.; Anderson G.; Kubera M.; Carvalho A.F.; Maes M.; The role of aberrations in the immune-inflammatory response system (IRS) and the compensatory immune-regulatory reflex system (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia. Mol Neurobiol 2020,57(2),778-797","journal-title":"Mol Neurobiol"},{"key":"ref=9","first-page":"401","volume":"41","author":"Orellana G.","year":"2013","unstructured":"Orellana G.; Alvarado L.; Mu\u00f1oz-Neira C.; \u00c1vila R.; M\u00e9ndez M.F.; Slachevsky A.; Psychosis-related matricide associated with a lesion of the ventromedial prefrontal cortex. J Am Acad Psychiatry Law 2013,41(3),401-406","journal-title":"J Am Acad Psychiatry Law"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fpsyt.2013.00035","volume":"4","author":"Orellana G.","year":"2013","unstructured":"Orellana G.; Slachevsky A.; Executive functioning in schizophrenia. Front Psychiatry 2013,4,35","journal-title":"Front Psychiatry"},{"key":"ref=11","author":"Swan M.","unstructured":"Swan M.; In: Next-generation personal genomic studies: extending\n\tsocial intelligence genomics to cognitive performance genomics in quantified creativity and thinking fast and slow, Proceedings of the 2013 AAAI Spring Symposium, Stanford, Clifornia, USA, March 27, 2013."},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pnpbp.2012.06.014","volume":"42","author":"Anderson G.","year":"2013","unstructured":"Anderson G.; Maes M.; Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2013,42,5-19","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/0004867414533012","volume":"48","author":"Davis J.","year":"2014","unstructured":"Davis J.; Moylan S.; Harvey B.H.; Maes M.; Berk M.; Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry 2014,48(6),512-529","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neubiorev.2016.03.017","volume":"65","author":"Davis J.","year":"2016","unstructured":"Davis J.; Eyre H.; Jacka F.N.; Dodd S.; Dean O.; McEwen S.; Debnath M.; McGrath J.; Maes M.; Amminger P.; McGorry P.D.; Pantelis C.; Berk M.; A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev 2016,65,185-194","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1007\/s12035-019-1552-z","volume":"56","author":"Maes M.","year":"2019","unstructured":"Maes M.; Moraes J.B.; Congio A.; Bonifacio K.L.; Barbosa D.S.; Vargas H.O.; Michelin A.P.; Carvalho A.F.; Nunes S.O.V.; Development of a novel staging model for affective disorders using partial least squares bootstrapping: effects of lipid-associated antioxidant defenses and neuro-oxidative stress. Mol Neurobiol 2019,56(9),6626-6644","journal-title":"Mol Neurobiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0165-1781(90)90057-C","volume":"34","author":"Maes M.","year":"1990","unstructured":"Maes M.; Schotte C.; Maes L.; Cosyns P.; Clinical subtypes of unipolar depression: Part II. Quantitative and qualitative clinical differences between the vital and nonvital depression groups. Psychiatry Res 1990,34(1),43-57","journal-title":"Psychiatry Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.psychres.2012.03.031","volume":"200","author":"Maes M.","year":"2012","unstructured":"Maes M.; Twisk F.N.; Johnson C.; Myalgic Encephalomyelitis (ME), Chronic Fatigue Syndrome (CFS), and Chronic Fatigue (CF) are distinguished accurately: results of supervised learning techniques applied on clinical and inflammatory data. Psychiatry Res 2012,200(2-3),754-760","journal-title":"Psychiatry Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s11011-018-0208-4","volume":"33","author":"Kanchanatawan B.","year":"2018","unstructured":"Kanchanatawan B.; Sriswasdi S.; Thika S.; Sirivichayakul S.; Carvalho A.F.; Geffard M.; Kubera M.; Maes M.; Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning. Metab Brain Dis 2018,33(4),1053-1067","journal-title":"Metab Brain Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jep.12945","volume":"24","author":"Kanchanatawan B.","year":"2018","unstructured":"Kanchanatawan B.; Sriswasdi S.; Thika S.; Stoyanov D.; Sirivichayakul S.; Carvalho A.F.; Geffard M.; Maes M.; Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis. J Eval Clin Pract 2018,24(4),879-891","journal-title":"J Eval Clin Pract"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"7822","DOI":"10.1007\/s12035-019-01647-0","volume":"56","author":"Al-Hakeim H.K.","year":"2019","unstructured":"Al-Hakeim H.K.; Al-Fadhel S.Z.; Al-Dujaili A.H.; Carvalho A.; Sriswasdi S.; Maes M.; Development of a novel neuro-immune and opioid-associated fingerprint with a cross-validated ability to identify and authenticate unknown patients with major depression: far beyond differentiation, discrimination, and classification. Mol Neurobiol Epub ahead of print2019,56(11),7822-7835","journal-title":"Mol Neurobiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1600-0447.1991.tb05580.x","volume":"83","author":"Maes M.","year":"1991","unstructured":"Maes M.; Vandervorst C.; Suy E.; Minner B.; Raus J.; A multivariate study of simultaneous escape from suppression by dexamethasone of urinary free cortisol, plasma cortisol, adrenocorticotropic hormone and beta-endorphin in melancholic patients. Acta Psychiatr Scand 1991,83(6),480-491","journal-title":"Acta Psychiatr Scand"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","volume":"68","author":"Keefe R.S.E.","year":"2004","unstructured":"Keefe R.S.E.; Goldberg T.E.; Harvey P.D.; Gold J.M.; Poe M.P.; Coughenour L.; The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004,68(2-3),283-297","journal-title":"Schizophr Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0165-1781(89)90153-4","volume":"30","author":"Kirkpatrick B.","year":"1989","unstructured":"Kirkpatrick B.; Buchanan R.W.; McKenney P.D.; Alphs L.D.; Carpenter W.T.; The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989,30(2),119-123","journal-title":"Psychiatry Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"Kay S.R.","year":"1987","unstructured":"Kay S.R.; Fiszbein A.; Opler L.A.; The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987,13(2),261-276","journal-title":"Schizophr Bull"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/S0007125000291496","author":"Andreasen N.C.","year":"1989","unstructured":"Andreasen N.C.; The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989(7),49-58","journal-title":"Br J Psychiatry Suppl"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"Overall J.E.","year":"1962","unstructured":"Overall J.E.; Gorham D.R.; The brief psychiatric rating scale. Psychol Rep 1962,10,799-812","journal-title":"Psychol Rep"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"Hamilton M.","year":"1960","unstructured":"Hamilton M.; A rating scale for depression. J Neurol Neurosurg Psychiatry 1960,23,56-62","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"8885","DOI":"10.1007\/s12035-018-1016-x","volume":"55","author":"Maes M.","year":"2018","unstructured":"Maes M.; Carvalho A.F.; The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. Mol Neurobiol 2018,55(12),8885-8903","journal-title":"Mol Neurobiol"},{"key":"ref=29","unstructured":"The Unscrambler Appendices: Method References 2019 CAMOAvailable from \n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.camo.com\/helpdocs\/The_Unscrambler_Method_References.pdf\">www.camo.com\/helpdocs\/The_Unscrambler_ Method_References.pdf (Accessed on March 19, 2019)","journal-title":"The Unscrambler Appendices: Method References 2019"},{"key":"ref=30","author":"Ringle C.M.","unstructured":"Ringle C.M.; Wende S.; Becker J-M.;  SmartPLS 3. B\u00f6nningstedt:\n\tSmartPLS, Available from\n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.smartpls.com\">http:\/\/www.smartpls.com (Accessed on 2015)"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.20944\/preprints201909.0095.v1","volume":"2019090095","author":"Matsumoto A.K.","year":"2019","unstructured":"Matsumoto A.K.; Maes M.; Maes A.; Michelin A.P.; de Oliveira Seme\u00e3o L.; de Lima Pedr\u00e3o J.V.; In Schizophrenia, PON1 Q192R genotypes and\/or lowered paraoxonase 1 (PON1) enzymatic activity are significantly associated with the deficit syndrome, negative symptoms, formal thought disorders, psychomotor retardation, excitation and increased IGA levels to gram-negative microbiota. Preprints 2019,2019090095","journal-title":"Preprints"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s12640-019-00139-2","volume":"37","author":"Stoyanov D.","year":"2020","unstructured":"Stoyanov D.; The reification of diagnosis in psychiatry. Neurotox Res 2020,37,772-774","journal-title":"Neurotox Res"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T07:52:57Z","timestamp":1596009177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178749\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,17]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,5,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200128143948","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}